CN1665539A - 基于新抗胆碱能剂及egfr激酶抑制剂的新颖药物组合物 - Google Patents

基于新抗胆碱能剂及egfr激酶抑制剂的新颖药物组合物 Download PDF

Info

Publication number
CN1665539A
CN1665539A CN038161370A CN03816137A CN1665539A CN 1665539 A CN1665539 A CN 1665539A CN 038161370 A CN038161370 A CN 038161370A CN 03816137 A CN03816137 A CN 03816137A CN 1665539 A CN1665539 A CN 1665539A
Authority
CN
China
Prior art keywords
amino
oxo
quinazoline
chloro
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN038161370A
Other languages
English (en)
Chinese (zh)
Inventor
米歇尔·佩雷特
克里斯托弗·J·M·米德
迈克尔·P·皮珀
伯吉特·琼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CN1665539A publication Critical patent/CN1665539A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN038161370A 2002-07-09 2003-06-26 基于新抗胆碱能剂及egfr激酶抑制剂的新颖药物组合物 Pending CN1665539A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10230751.2 2002-07-09
DE10230751A DE10230751A1 (de) 2002-07-09 2002-07-09 Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern

Publications (1)

Publication Number Publication Date
CN1665539A true CN1665539A (zh) 2005-09-07

Family

ID=29761746

Family Applications (1)

Application Number Title Priority Date Filing Date
CN038161370A Pending CN1665539A (zh) 2002-07-09 2003-06-26 基于新抗胆碱能剂及egfr激酶抑制剂的新颖药物组合物

Country Status (16)

Country Link
EP (2) EP1521595B1 (enExample)
JP (1) JP2005537250A (enExample)
CN (1) CN1665539A (enExample)
AT (1) ATE320269T1 (enExample)
AU (1) AU2003242771B2 (enExample)
BR (1) BR0312507A (enExample)
CA (1) CA2492037A1 (enExample)
DE (2) DE10230751A1 (enExample)
ES (1) ES2259769T3 (enExample)
MX (1) MXPA05000163A (enExample)
NZ (1) NZ538096A (enExample)
PL (1) PL374022A1 (enExample)
RU (1) RU2317828C2 (enExample)
TW (1) TW200520757A (enExample)
WO (1) WO2004004775A1 (enExample)
ZA (1) ZA200409676B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002239410B2 (en) 2000-10-31 2008-05-01 Eisai Inc. CYP1B1 nucleic acids and methods of use
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
EP1781298B1 (de) * 2004-04-22 2012-01-04 Boehringer Ingelheim International GmbH Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
JP2008532973A (ja) * 2005-03-09 2008-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とｐｄｅ５−阻害剤に基づく新規な医薬組成物
EP1917253B1 (de) 2005-08-15 2015-01-07 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von betamimetika
PT2402319T (pt) 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
WO2010054285A2 (en) 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2927925A (en) * 1960-03-08 Scopine and sgopoline esters of alpha
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
IL107120A (en) 1992-09-29 1997-09-30 Boehringer Ingelheim Int Atomising nozzle and filter and spray generating device
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
DE19536903C2 (de) 1995-10-04 1998-09-10 Boehringer Ingelheim Int Vorrichtung zum Haltern eines fluidischen Bauteils
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE19545226C1 (de) 1995-12-05 1997-06-19 Boehringer Ingelheim Int Sperrspannwerk für einen federbetätigten Abtrieb
TW436485B (en) * 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
NZ516633A (en) * 1999-06-21 2004-09-24 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10050994A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
DE10206505A1 (de) * 2002-02-16 2003-08-28 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern
DE10203753A1 (de) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
TW200520757A (en) 2005-07-01
DE50302675D1 (de) 2006-05-11
ATE320269T1 (de) 2006-04-15
PL374022A1 (en) 2005-09-19
BR0312507A (pt) 2005-04-12
WO2004004775A1 (de) 2004-01-15
JP2005537250A (ja) 2005-12-08
EP1658860A1 (de) 2006-05-24
ES2259769T3 (es) 2006-10-16
AU2003242771A1 (en) 2004-01-23
EP1521595A1 (de) 2005-04-13
NZ538096A (en) 2007-04-27
CA2492037A1 (en) 2004-01-15
RU2005103397A (ru) 2006-03-20
ZA200409676B (en) 2006-05-31
RU2317828C2 (ru) 2008-02-27
MXPA05000163A (es) 2005-04-08
EP1521595B1 (de) 2006-03-15
AU2003242771B2 (en) 2009-07-30
DE10230751A1 (de) 2004-01-22

Similar Documents

Publication Publication Date Title
US7776315B2 (en) Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20030158196A1 (en) Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US20050165013A1 (en) Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors
CN1649588A (zh) 基于抗胆碱能药物及pde－iv抑制剂的新颖药物组合物
US20110076238A1 (en) Compounds for the treatment of proliferative processes
US20100310477A1 (en) Pharmaceutical compositions based on anticholingerics and additional active ingredients
CN1633305A (zh) 基于抗胆碱能剂和egfr激酶抑制剂的新颖药物组合物
CN1237970C (zh) 含提欧川平盐的溶液的可吸入制剂
CN1646126A (zh) 包含类固醇及新颖抗胆碱酯酶剂的药物
JP4620730B2 (ja) ベータ作動薬を含む吸入用エアロゾル製剤
US20060239935A1 (en) Compositions for inhalation
AU2003242771B2 (en) Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase
HK1081460A (en) Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase
HK1077748A (en) New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
CA2551900A1 (en) Novel pharmaceutical combinations containing scopine or tropic acid esters and egfr-kinase inhibitors
CN1769286A (zh) 一种治疗鼻腔分泌过度和慢阻肺的化合物以及药物组合物
CA2600636A1 (en) New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors
HK1078872A (en) Medicaments containing betamimetic drugs and a novel anticholinesterase drug
US20050203088A1 (en) Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors
HK1060569B (en) Inhalative solution formulation containing a tiotropium salt
KR20050016999A (ko) 신규한 항콜린제 및 ｅｇｆｒ-키나제의 억제제를 기초로한 신규한 약물 조성물
HK1080736A (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
HK1078794A (en) Medicaments containing steroids and a novel anticholinesterase drug
HK1085119A (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1081460

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1081460

Country of ref document: HK